Clinical Trials Directory

Trials / Unknown

UnknownNCT02334904

Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
University of British Columbia · Academic / Other
Sex
All
Age
12 Years
Healthy volunteers
Accepted

Summary

Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders. Recent evidence suggests that some atypical antipsychotic drugs can maintain or increase brain volumes. Thus, we plan to use MRI scans to measure changes in brain morphology in subjects recently diagnosed with bipolar or psychosis disorders who are taking the atypical antipsychotic drugs aripiprazole or risperidone. Secondary objectives include taking blood samples for fasting metabolic indices and neuropsychiatric measures for comparisons between drug treatments.

Detailed description

The purpose of this study is to use a direct measure of brain volume and matter (by means of MRI) to determine if there is a differential effect between aripiprazole and risperidone on brain morphology in participants with first-episode psychosis. A secondary objective is to see if fasting metabolic indices measured in the blood (i.e. glucose, insulin, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, adiponectin and leptin) are also correlated to changes in brain morphology or symptom severity (as measured by neuropsychiatric assessments).

Conditions

Interventions

TypeNameDescription
DRUGAripiprazoleTo be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
DRUGRisperidoneTo be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).

Timeline

Start date
2014-07-01
Primary completion
2016-06-01
Completion
2016-06-01
First posted
2015-01-08
Last updated
2016-06-01

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02334904. Inclusion in this directory is not an endorsement.